

2011 References

1. ACCF/AHA. (2007). Clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. *Circulation*, 115, 402-426.
2. ACOG Committee Opinion No. 420, November 2008: Hormone therapy and heart disease. *Obstetrics & Gynecology*, 112(5), 1189-92.
3. ACOG Committee Opinion No. 483: Primary and preventive care: periodic assessments. (2011). *Obstetrics & Gynecology*, 117(4), 1008-15.
4. ACOG Task Force for Hormone Therapy. (2004). Summary of balancing risks and benefits. *Obstetrics & Gynecology*, 104 (4 Suppl), 1S-129S.
5. AGREE Collaboration. (2003). Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. *Quality & Safety in Health Care*, 12, 18-23.
6. Akesson A, et al. (2007). Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myocardial infarction in women. *Archives of Internal Medicine*, 167, 2122-2127.
7. American College of Obstetricians and Gynecologists (ACOG). Smoking Cessation during Pregnancy. ACOG Committee Opinion, number 316, October 2005.
8. American Diabetes Association. (2010). Diagnosis and treatment of diabetes mellitus. *Diabetes Care*, 33 (Supplement 1), S62-S69.
9. American Diabetes Association. (2011). Standards of medical care in diabetes — 2011. *Diabetes Care*, 34 (Supplement 1), S11-S61.
10. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE,

- Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. *Journal of the American Medical Association*, 291(14), 1701-12.
11. Antiplatelet Trialists' Collaboration. (1994). Collaborative overview of randomized trials of antiplatelet therapies in various categories of patients. *BMJ*, 308, 81-106.
 12. Arias E. (2010). United States life tables by Hispanic origin. CDC/National Center for Health Statistics. *Vital Health Statistics*, 2(152).
 13. Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L, Lichtenstein AH, Kumanyika S, Kraus WE, Fleg JL, Redeker NS, Meininger JC, Banks J, Stuart-Shor EM, Fletcher BJ, Miller TD, Hughes S, Braun LT, Kopin LA, Berra K, Hayman LL, Ewing LJ, Ades PA, Durstine JL, Houston-Miller N, Burke LE; on behalf of the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing. (2010). Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. *Circulation*, 122, 406-441.
 14. Assmann G, Cullen P, Schulte H. (2002). Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. *Circulation*, 105, 310-315.
 15. Bader P, et al. (2009). An algorithm for tailoring pharmacotherapy for smoking cessation: Results from a Delphi panel of international experts. *Tobacco Control*, 18, 34-42.

16. Bandura A, Cervone D. (1983). Self-evaluative and self-efficacy mechanisms governing the motivational effects of goal systems. *Journal of Personality & Social Psychology*, 45, 1017-1028.
17. Banerjee M and Cruickshank JK. (2006). Pregnancy as the prodrome to vascular dysfunction and cardiovascular risk. *Nature Clinical Practice Cardiovascular Medicine*, 3, 596–603.
18. Barnhart J, Lewis V, Houghton JL, Charney P. (2007). Physician knowledge levels and barriers to coronary risk prevention in women: Survey results from the Women and Heart Disease Physician Education Initiative. *Women's Health Issues*, 17, 93-100.
19. Barrett-Connor E, et al. (2006). Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *New England Journal of Medicine*, 355, 125-37.
20. Beach MC, Cooper LA, Robinson KA, et al. (Johns Hopkins University Evidence-based Practice Center, Baltimore, MD). (2004). Strategies for improving minority healthcare quality. Final report. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Jan. Report No.: 04-E008-02. Contract No.: 290-02-0018.
21. Befort CA, Donnelly JE, Sullivan DK, Ellerbeck EF, Perri MG. (2010). Group versus individual phone-based obesity treatment for rural women. *Eating Behaviors*, 11, 11-17.
22. Bellamy L, Casas JP, Hingorani AD, Williams DJ. (2007). Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*, 335, 974.
23. Betancourt JR, Green AR, and Carrillo JE. (2002). Cultural competence in health care: Emerging frameworks and practical approaches. The Commonwealth Fund.
24. Bobrie G, Postel-Vinay N, Delonca J, Corvol P; SETHI Investigators. (2007). Self-measurement and self-titration in hypertension: A pilot telemedicine study. *American Journal of Hypertension*, 20, 1314-1320.

25. Bodenheimer T. (2008). Coordinating care — A perilous journey through the health care system. *New England Journal of Medicine*, 358,1064-1071.
26. Boersma C, Carides GW, Atthobari J, Voors AA, Postma MJ. (2007). An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. *Clinical Therapeutics*, 29, 963-971.
27. Bolin K, Lindgren B, Willers S. (2006). The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. *Chest*, 129, 651-660.
28. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators. (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction. *New England Journal of Medicine*, 354(15), 1578-88.
29. Boudreaux MY, et al. (2006). Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow up. *Current Diabetes Reports*, 6(1), 77-83.
30. Cabana MD, Kim C. (2003). Physician adherence to preventive cardiology guidelines for women. *Womens Health Issues*,13, 142-149.
31. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. (1999). Why don't physicians follow clinical practice guidelines? A framework for improvement. *Journal of the American Medical Association*, 282,1458-1465.
32. Carr MC, et al. (2000). Changes in LDL density across the menopausal transition. *Journal of Investigative Medicine*, 48, 245-250.
33. Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM. (2008). Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. *Preventive Medicine*, 47, 619-623.

34. Centers for Disease Control and Prevention. U.S. Obesity Trends: Trends by State 1985–2010. Behavioral Risk Factor Surveillance System (BRFSS). Available at: <http://www.cdc.gov/obesity/data/trends.html>.
35. Centers for Disease Control and Prevention. (2005). Racial/Ethnic Disparities in Prevalence, Treatment, and Control of Hypertension—United States, 1999—2002. *Morbidity & Mortality Weekly Report*, 54(01), 7-9.
36. Chandra NC, et al. (1998). Observations of the treatment of women in the United States with myocardial infarction: A report from the National Registry of Myocardial Infarction-I. *Archives of Internal Medicine*, 158, 981-988.
37. Cho L, et al. (2008). Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland Clinic Prevention Database study. *Journal of Women's Health*, 17, 1-7.
38. Chobanian AV, Bakris GL, Black HR, , Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. (2003). National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*, 42, 1206-1252.
39. Chou AF, et al. (2007). Gender disparities in the quality of cardiovascular disease care in private managed care plans. *Women's Health Issues*, 17, 120-130.
40. Clark CE, Smith LFP, Taylor RS, and Campbell JL. (2010). Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. *BMJ*, 341, c3995.
41. Cohen MG, Fonarow GC, Peterson ED, Moscucci M, Dai D, Hernandez AF, Bonow RO, Smith SC, JR. (2010). Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get with the Guidelines-Coronary Artery Disease Program. *Circulation*, 121, 2294-2301.

42. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. (2003). Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *European Heart Journal*, 24, 987-1003.
43. Cox RH, White AH, Gaylord CK. (2003). A video lesson series is effective in changing the dietary intakes and food-related behaviors of low-income homemakers. *Journal of the American Dietetic Association*, 103, 1488-1493.
44. Craig BM, Tseng DS. (2002). Cost-effectiveness of gastric bypass for severe obesity. *American Journal of Medicine*, 113, 491-498.
45. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. (2003). Medication compliance feedback and monitoring; in a clinical trial predictors and outcomes. *Value Health*, 6, 566-573.
46. D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. (2008). General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*, 117, 743-753.
47. Darba J, Izquierdo I, Pontes C, Navas C, Rovira J. (2002). Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. *Pharmacoeconomics*, 20, 195-201.
48. Davis AM, Vinci LM, Tochi M et al. (2007). Cardiovascular health disparities: A systematic review of health care interventions. *Medical Care Research & Review*, 64, 29S-99S.
49. Delahanty LM, Sonnenberg LM, Hayden D, Nathan DM. (2001). Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial. *Journal of the American Dietetic Association*, 101, 1012-1023.
50. Dimatteo MR. (2004). Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. *Medical Care*, 42, 197-199..

51. Doroodchi H, Abdolrasulnia M, Foster JA, Foster E, Turakhia MP, Skelding KA, Sagar K, Casebeer LL. (2008). Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. *BMC Family Practice*, 9, 42-50.
52. Edejer TTT. (2006). Improving the use of research evidence in guideline development: 11. Incorporating considerations of cost-effectiveness, affordability and resource implications. *Health Research Policy & Systems*, 4, 23.
53. Egan BM, Zhao Y, Axon RN. (2010). US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. *Journal of the American Medical Association*, 303, 2043-2050.
54. Ekman M, Bienfait-Beuzon C, Jackson J. (2008). Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. *Journal of Human Hypertension*, 22, 845-855.
55. Espeland MA, et al. (1998). Effect of postmenopausal therapy on glucose and insulin concentrations. *Diabetes Care*, 21, 1589-1595.
56. Eriksson M, et al. (1999). Relationship between plasma fibrinogen and coronary heart disease in women. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 19, 67-72.
57. Fang WL, Goldstein, AO, Butzen AY, Hartsock SA, Hartmann KE, Helton M, Lohr, JA. (2004). Smoking cessation in pregnancy: A review of postpartum relapse prevention strategies. *Journal of the American Board of Family Medicine*, 17(4), 264-275.
58. Ferris A, Robertson RM, Fabunmi R, Mosca L. (2005). American Heart Association and American Stroke Association national survey of stroke risk awareness among women. *Circulation*, 111, 1321-1326.
59. Filion K, Abenhaim H, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, Tremblay M, Eisenberg M. (2011). The effect of smoking cessation counselling in pregnant women: a meta-analysis of

- randomised controlled trials. *British Journal of Obstetrics and Gynecology*, 118(12), 1422-1428.
60. Fiore MC, et al. (2000). Treating tobacco use and dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. June 2000.
 61. Fiore MC, Jaén CR, Baker TB, et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf.
 62. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. (2007). Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. *New England Journal of Medicine*, 356, 2388-2398.
 63. Francke AL, Smit MC, de Veer AJ, Mistiaen P. (2008). Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. *BMC Medical Informatics & Decision Making*, 8, 38-48.
 64. Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F. (2001). Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. *Pharmacoeconomics*, 19, 411-420.
 65. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for

- Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). *Circulation*, 114, e257-e354.
66. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. (2001). Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. *Journal of the American Medical Association*, 285, 2864-2870.
 67. Gallo LC, Penedo FJ, Espinosa de los Monteros K, Arguelles W. (2009). Resiliency in the face of disadvantage: Do Hispanic cultural characteristics protect health outcomes? *Journal of Personality*, 77, 1707-1746.
 68. Garovic VD and Hayman SR. (2007). Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. *Nature Clinical Practice Nephrology*, 3, 613–622.
 69. Gholizadeh L, Davidson P. (2008). More similarities than differences: An international comparison of CVD mortality and risk factors in women. *Health Care for Women International*, 29, 3-22.
 70. Global Program on Evidence for Health Policy. (2003). Guidelines for WHO Guidelines. EPI/GPE/EQC/2003.I. World Health Organization, Geneva.
 71. Grady et al. (1992). Hormone therapy to prevent disease and prolong life in postmenopausal women. *Annals of Internal Medicine*, 117, 1016-1037.
 72. Graves N, Barnett AG, Halton KA, Veerman JL, Winkler E, Owen N, Reeves MM, Marshall A, Eakin E. (2009). Cost-effectiveness of a telephone-delivered intervention for physical activity and diet. *PLoS One*, 4, e7135.
 73. Greving JP, Buskens E, Koffijberg H, Algra A. (2008). Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. *Circulation*, 117, 2875-2883.
 74. Group HPS. (2009). Statin cost-effectiveness in the United States for people at different vascular risk levels. *Circulation: Cardiovascular & Quality Outcomes*, 2, 65-72.

75. Gunderson EP, et al. (2010). Duration of lactation and incidence of the metabolic syndrome in women of reproductive age according to gestational diabetes mellitus status: A 20-year prospective study in CARDIA (coronary artery risk development in young adults). *Diabetes*, 59, 495-504.
76. Grundy SM, et al. (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*, 110, 227-239.
77. Grundy SM, et al. (2005). Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Circulation*, 112, 2735-2752.
78. Guidelines International Network. (2010). International Guideline Library. Available at: <http://www.g-i-n.net/library>. Accessed October 16, 2010.
79. Gunderson EP, Jacobs DR Jr, Chiang V, Lewis CE, Feng J, Quesenberry CP Jr, Sidney S. (2010). Duration of lactation and incidence of the metabolic syndrome in women of reproductive age according to gestational diabetes mellitus status: a 20-Year prospective study in CARDIA (Coronary Artery Risk Development in Young Adults). *Diabetes*, 59(2), 495-504.
80. Hannaford P, et al. (1997). Cardiovascular sequelae of toxemia of pregnancy. *Heart*, 77, 154-158.
81. Harpaz D, et al. (1996). Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. *American Journal of Cardiology*, 78, 1215-1219.
82. Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L. (2008). Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: An analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of General Internal Medicine*, 23, 509-516.

83. Hendrix KH, et al. (2005). Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. *Ethnicity & Disease*, 15, 1-16.
84. Heron M. (2010). Deaths: Leading causes for 2006. National vital statistics reports; vol 58, no 14. Hyattsville, MD: National Center for Health Statistics.
85. Hernandez AF, et al. (2007). Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. *Journal of the American Medical Association*, 298, 1535-1532.
86. Hertz RP, Unger AN, Cornell JA, Saunders E. (2005). Racial disparities in hypertension prevalence, awareness and management. *Archives of Internal Medicine*, 165, 2098–2104.
87. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. (2007). Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. *BMJ*, 335, 136-147.
88. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand S-LT, O'Donnell CJ, Smith SC Jr, Wilson PWF; on behalf of the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. (2009). Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. *Circulation*, 119, 2408–2416.
89. Hokanson JE, Austin MA. (1996). Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *Journal of Cardiovascular Risk*, 3, 213-219.
90. Hsia J, Rodabough RJ, Manson JE, Liu S, Freiberg MS, Graettinger W, Rosal MC, Cochrane B, Lloyd-Jones D, Robinson JG, Howard BV. (2010). Evaluation

- of the American Heart Association cardiovascular disease prevention guideline for women. *Circulation: Cardiovascular & Quality Outcomes*, 128-134.
91. Hulley S, et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *Journal of the American Medical Association*, 280, 605-613.
 92. Hurley SF, Matthews JP. (2007). The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. *Cost Effectiveness & Resource Allocation*, 5, 2-11.
 93. Hyre AD, Muntner P, Menke A, Raggi P, He J. (2007). Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. *Annals of Epidemiology*, 17, 548-555.
 94. Institute of Medicine, Committee on Quality Health Care in America. (2001). Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press.
 95. Institute of Medicine, Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. (2003). Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press.
 96. ISIS-2 Collaborative Group. (1988). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither. *Lancet*, 8607, 349-360.
 97. Jackevicius CA, Mamdani M, Tu JV. (2002). Adherence with statin therapy in elderly patients with and without acute coronary syndromes. *Journal of the American Medical Association*, 288, 462-467.
 98. Jensen C, Flum DR. (2005). The costs of nonsurgical and surgical weight loss interventions: is an ounce of prevention really worth a pound of cure? *Surgery for Obesity & Related Diseases*, 1, 353-357.
 99. Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA. (2005). A model for cost-effectiveness analyses of smoking cessation interventions applied to a

- Quit-and-Win contest for mothers of small children. *Scandinavian Journal of Public Health*, 33, 343-352.
100. Joint Commission. (2007). The Joint Commission announces the 2008 National Patient Safety Goals and Requirements. *The Joint Commission Perspectives*, 27, 9-22.
 101. Jonsson B, Buxton M, Hertzman P, Kahan T, Poulter N. (2001). Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). *Journal of Human Hypertension*, 15, S53-56.
 102. Kaaja RJ, Greer IA. (2005). Manifestations of chronic disease during pregnancy. *Journal of the American Medical Association*, 294, 2751-2757.
 103. Keil U. (2000). Coronary artery disease: the role of lipids, hypertension, and smoking. *Basic Research in Cardiology*, 95, I52-I58.
 104. Kim C, et al. (2002). Gestational diabetes and the incidence of type 2 diabetes: A systemic review. *Diabetes Care*, 25(10), 1862-1868.
 105. Kleindorfer D, Khoury J, Broderick JP, Rademacher E, Woo D, Flaherty ML, Alwell K, Moomaw CJ, Schneider A, Pancioli A, Miller R, Kissela BM. (2009). Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment. *Stroke*, 40, 2502-2506.
 106. Kok G, van den BB, Mullen PD. (1997). Effectiveness of health education and health promotion: meta-analyses of effect studies and determinants of effectiveness. *Patient Education & Counseling*, 30, 19-27.
 107. Kris-Etherton PM, Harris WS, and Appel LJ. (2003). Omega-3 fatty acids and cardiovascular disease: New recommendations from the American Heart Association. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 23, 151-152.
 108. Krolewski AS, et al. (1991). Evolving natural history of coronary artery disease in diabetes mellitus. *American Journal of Medicine*, 90, 56S-61S.

109. LaCroix AZ, Chlebowski RT, Manson JE, et al. (2011). Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. *Journal of the American Medical Association*, 305(13), 1305-1314.
110. Lakoski SG, Greenland P, Wong ND, Schreiner PJ, Herrington DM, Kronmal RA, Liu K, Blumenthal RS. (2007). Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). *Archives of Internal Medicine*, 167, 2437-2442.
111. Lapuerta P, Simon T, Smitten A, Caro J. (2001). Assessment of the association between blood pressure control and health care resource use. *Clinical Therapeutics*, 23, 1773-1782.
112. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. (2005). Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: A randomized controlled trial. *Journal of the American Medical Association*, 294(1), 56-65.
113. Lewis V, Barnhart J, Houghton JL, Charney P. (2010). A brief office educational intervention improved referral rates for hypertension control in women. *International Journal of Cardiology*, 139(2), 204-206.
114. Lewis WR, Ellrodt AG, Peterson E, Hernandez AF, LaBresh KA, Cannon CP, Pan W, Fonarow GC. (2009). Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the Get with Guidelines Quality Improvement Program. *Circulation: Cardiovascular Quality and Outcomes*, 2, 633-641.
115. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. (2006). Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. *Circulation*, 114, 82-96.

116. Limacher MC. (2002). Hormones and heart disease: What we thought, what we have learned, and what we still need to know. *Transactions of the American Clinical & Climatological Association*, 113, 31-41.
117. Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT Trial Investigators. (2008). Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. *Heart*, 94, e4.
118. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (2010). Executive summary: Heart disease and stroke statistics-2010 update. A report from the American Heart Association. *Circulation*, 121, 948-954.
119. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. (2010). Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation*, 121, 586-613.
120. Lloyd-Jones DM, Leip EP, Larson MG, et al. (2006). Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation*, 113(6), 791-798.
121. Lloyd-Jones DM, Leip EP, Larson MG, Vasan RS, Levy D. (2005). Novel approach to examining first cardiovascular events after hypertension onset. *Hypertension*, 45, 39-45.

122. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PWF, Wolf PA, Levy D. (2006). Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation*, 113, 791-798.
123. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR; HOPE and HOPE-TOO Trial Investigators. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. *Journal of the American Medical Association*, 293(11), 1338-47.
124. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. (2006). Global Burden of Disease and Risk Factors. Oxford University Press and World Bank. 2006.
125. Lorig KR, Ritter PL, Dost A, Plant K, Laurent DD, Mcneil I. (2008). The expert patients programme online: A 1-year study of an Internet-based self-management programme for people with long-term conditions. *Chronic Illness*, 4, 247-256.
126. Loscalzo J. (2006). Homocysteine trials — Clear outcomes for complex reasons. *New England Journal of Medicine*, 354, 1629 – 1632.
127. Magnussen EB, et al. (2009). Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. *Obstetrics & Gynecology*, 114, 961-70.
128. Malone DC, Raebel MA, Porter JA, Lanty FA, Conner DA, Gay EC, Merenich JA, Vogel EA. (2005). Cost-effectiveness of sibutramine in the LOSE Weight Study: Evaluating the role of pharmacologic weight-loss therapy within a weight management program. *Journal of Managed Care Pharmacy*, 11, 458-468.
129. Manson JE, et al. (1995). Body weight and mortality among women. *New England Journal of Medicine*, 333, 677-685.
130. Manson JE, et al. (1999). A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. *New England Journal of Medicine*, 341, 650-658.

131. Markides KS, Eschbach K. (2005). Aging, migration, and mortality: Current status of research on the Hispanic paradox. *Journals of Gerontology, Series B: Social Sciences and Psychological Sciences*, 60, 68-75.
132. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. (2010). Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: Findings from the National Health and Nutrition Examination Survey 2003 to 2006. *Circulation: Cardiovascular Quality & Outcomes*, 3, 8-14.
133. Marma AK, Lloyd-Jones DM. (2009). Systematic examination of updated Framingham Heart Study general cardiovascular risk profile. *Circulation*, 120, 384-390.
134. Maron DJ. (2000). The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. *American Journal of Cardiology*, 86, 11L-14L.
135. Masley S, Phillips S, Copeland JR. (2001). Group office visits change dietary habits of patients with coronary artery disease--the Dietary Intervention and Evaluation Trial (D.I.E.T.). *Journal of Family Practice*, 50, 235-239.
136. Mendelsohn ME, Karas RH. (1999). The protective effects of estrogen on the cardiovascular system. *New England Journal of Medicine*, 340, 1801-1811.
137. Miller RR, Sales AE, Kopjar B, Fihn SD, Bryson CL. (2005). Adherence to heart-healthy behaviors in sample of the U.S. population. *Preventing Chronic Disease*, 2, A18.
138. Miller VM, et al. (2009). Using basic science to design a clinical trial: Baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). *Journal of Cardiovascular Translational Research*, 2, 228-239.
139. Miller W, Rollnick S. (2002). Motivational Interviewing: Preparing People for Change. 2nd ed. New York: Guilford.
140. Miniño AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: Final Data for 2000. National vital statistics reports; vol 50 no 15. Hyattsville, Maryland: National Center for Health Statistics. 2002.

141. Montgomery AA, Fahey T, Ben-Shlomo Y, Harding J. (2003). The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: A Markov decision analysis. *Journal of Hypertension*, 21, 1753-1759.
142. Mosca L. (2008). Aspirin chemoprevention: One size does not fit all. *Circulation*, 117, 2844-2846.
143. Mosca L, et al. (2004). Evidence-based guidelines for cardiovascular disease prevention in women. *Circulation*, 109, 672-693.
144. Mosca L, et al. (2007). Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation*, 115, 1481-501.
145. Mosca L, Grundy S, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson T, Redberg R, Smith S, Winston M, Zinberg S: (1999). AHA/ACC Consensus Panel Statement: A Guide to Preventive Cardiology for Women. *Circulation*, 99, 2480-2484.
146. Mosca L, Mochari H, Christian AH, Berra K, Taubert K, Mills T, Burdick KA, Simpson SL. (2006). National study of women's awareness, preventive action, and barriers to cardiovascular health. *Circulation*, 113, 525–534.
147. Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb K. (2010). Twelve-Year follow-up of American Women's Awareness of Cardiovascular Disease (CVD) Risk and Barriers to Heart Health. *Circulation: Cardiovascular & Quality Outcomes*, 3,120-127.
148. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CR, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. (2011). Effectiveness-based guidelines for the prevention of cardiovascular disease in

- women—2011 Update: A Guideline From the American Heart Association. *Circulation*, 123, 1243-1262.
149. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, Volcik K, Boerwinkle E, Ballantyne CM. (2010). Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. *Journal of the American College of Cardiology*, 55, 1600-1607.
 150. Narayan KM et al. (2003). Lifetime risk for diabetes mellitus in the United States. *Journal of the American Medical Association*, 290, 1884-1890.
 151. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*, 106, 3143–3421.
 152. National Heart, Lung, and Blood Institute (1998). Facts about the DASH eating plan. NIH publication no. 03-4082. Bethesda, MD.
 153. National Heart, Lung and Blood Institute. (1998). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.
 154. National Institute for Health and Clinical Excellence. (2010). Putting Guidance Into Practice. Available at: <http://www.nice.org.uk/usingguidance/>. Accessed October 16, 2010.
 155. Nohria A, et al. (1998). Gender differences in coronary artery disease in women: Gender differences in mortality after myocardial infarction: Why women fare worse than men. *Cardiology Clinics*, 16, 45-57.
 156. Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. (2008). Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. *Annals of Epidemiology*, 18, 222-229.

157. Oostenbrink JB, Tangelder MJ, Busschbach JJ, van Hout BA, Buskens E, Algra A, Lawson JA, Eikelboom BC, Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. (2001). Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. *Journal of Vascular Surgery*, 34, 254-262.
158. O'Meara JG, et al. (2004). Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. *Archives of Internal Medicine*, 164, 1313-1318.
159. Orth-Gomer K, et al. (2000). Marital stress worsens prognosis in women with coronary heart disease. *Journal of the American Medical Association*, 283, 3008-3014.
160. Oxman AD, Fretheim A, Schünemann HJ. (2006). Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation. *Health Research Policy and Systems*, 12-14.
161. Pearson TA, et al. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*, 107, 499-511.
162. Pencina MJ, D'Agostino, Sr., RB, Larson MG, Massaro JM, Vasan RS. (2009). Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. *Circulation*, 119, 3078-3084.
163. Peterson LA, Woodard LD, Urech T, Daw C, Sookanan S. (2006). Does pay-for-performance improve the quality of health care? *Annals of Internal Medicine* 145, 265-272.
164. Pham HH, Schrag D, O'Malley AS, Wu B, Bach PB. (2007). Care patterns in Medicare and their implications for pay for performance. *New England Journal of Medicine*, 356, 1130-1139.
165. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D ; (2008). Call to action on use and reimbursement for home blood pressure monitoring: a

joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. *Hypertension*, 52, 10-29.

166. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ. (2009). The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: A systematic review and economic evaluation. *Health Technology Assessment*, 13, 1-190, 215-357, iii-iv Review.
167. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. (2007). Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. *Archives of Internal Medicine*, 167, 290-295.
168. Pollak KI, Alexander SC, Coffman CJ, Tulskey JA, Lyna P, Dolor RJ, James IE, Namenek Brouwer RJ, Manusov JRE, Ostbye T. (2010). Physician communication techniques and weight loss in adults: Project CHAT. *American Journal of Preventive Medicine*, 39(4), 321-328.
169. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P. (2010). Coronary artery calcium score and risk classification for coronary heart disease prediction. *Journal of the American Medical Association*, 303, 1610-1616.
170. Pradelli L, Iannazzo S, Zaniolo O. (2009). The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model. *American Journal Cardiovascular Drugs*, 9, 383-392.
171. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB Sr, Savage PJ, Levy D, Fox CS. (2009). Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. *Circulation*, 119, 1728-1725.
172. Prescott E, et al. (1998). Smoking and risk of myocardial infarction in women and men: Longitudinal population study. *BMJ*, 316, 1043-47.

173. Prior M, Guerin M, Gimmer-Somers K. (2008). The effectiveness of clinical guideline implementation strategies—A synthesis of systematic review findings. *Journal of Evaluation in Clinical Practice*, 14, 888-897.
174. Prochaska J, Norcross J, DiClemente C. (1984). Changing for Good: A Revolutionary Six Stage Program for Overcoming Bad Habits and Moving Your Life Positively Forward. New York: Avon Books, Inc.
175. Prochaska JO, DiClemente CC, Norcross JC. (1992). In search of how people change: Applications to addictive behavior. *American Psychologist*, 47, 1102-1114.
176. Quist-Paulsen P, Lydersen S, Bakke PS, Gallefoss F. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease. *European Journal of Cardiovascular Prevention & Rehabilitation*, 13, 274-280.
177. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. (2005). Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet*, 366, 1797-1803.
178. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW. (2009). AHA/ACCF 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease). *Circulation*, 120, 1296–1336.
179. Ridker PM, Buring JE, Rifai N, Cook NR. (2007). Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. *Journal of the American Medical Association*, 297, 611-619.
180. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd

- J, Willerson JT, Glynn RJ. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *New England Journal of Medicine*, 359, 2195-2207.
181. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. (2009). Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. *Lancet*, 373(9670), 1175-82.
 182. Ridker PM, Hennekens CH, Buring JE, Rifai N. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *New England Journal of Medicine*, 342(12), 836-43.
 183. Riegel B, Moser DK, Anker SD, Appel LJ, Dunbar SB, Grady KL, Gurvitz MZ, Havranek EP, Lee CS, Lindenfeld J, Peterson PN, Pressler SJ, Schocken DD, Whellan DJ, on behalf of the American Heart Association Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Nutrition, Physical Activity, and Metabolism, and Interdisciplinary Council on Quality of Care and Outcomes Research. (2009). State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. *Circulation*, 120, 1141–1163.
 184. Roger VL, Go AS, Lloyd-Jones DM, et al. (2011). Heart disease and stroke statistics--2011 update: A report from the American Heart Association. *Circulation*, 123(4), e18-209.
 185. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2008). AHA Statistical Update, Heart Disease and Stroke Statistics—2008 Update, A Report from the American Heart Association

- Statistics Committee and Stroke Statistics Subcommittee. *Circulation*, 117, e25-e146.
186. Rubak S, Sandbæk A, Lauritzen T, & Christensen B. (2005). Motivational interviewing: A systematic review and meta-analysis. *British Journal of General Practice*, 55(513), 305-312.
 187. Sacks FM, et al. (2001). Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. *New England Journal of Medicine*, 344, 3-10.
 188. Saha S, Beach MC, and Cooper LA. (2008). Patient-centeredness, cultural competence and healthcare quality. *Journal of the National Medical Association*, 100, 1275-1285.
 189. Salem L, Devlin A, Sullivan SD, Flum DR. (2008). Cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding, and nonoperative weight loss interventions. *Surgery for Obesity & Related Diseases*, 4, 26-32.
 190. Salmon JE, Roman MJ. (2008). Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. *American Journal of Medicine*, 121, S3-8.
 191. Sattar N. (2004). Do pregnancy complications and CVD share common antecedents? *Atherosclerosis Supplements*, 5, 3-7.
 192. Sattar N & Greer IA. (2002). Pregnancy complications and maternal cardiovascular risk: Opportunities for intervention and screening. *BMJ*, 325(7356), 157-160.
 193. Scott LB, Allen JK. (2004). Providers perceptions of factors affecting women's referral to outpatient cardiac rehabilitation programs: an exploratory study. *Journal of Cardiopulmonary Rehabilitation*, 24, 387-391.
 194. Scottish Intercollegiate Guidelines Network. (2008). SIGN 50: A Guideline Developer's Handbook. Available at: <http://www.sign.ac.uk/guidelines/fulltext/50/index.html>. Accessed October 16, 2010.

195. Shah BR et al. (2008). Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. *Diabetes Care*, 31(8), 1668-1669.
196. Sherwood NE, Jeffery RW, Pronk NP, Boucher JL, Hanson A, Boyle R, Brelje K, Hase K, Chen V. (2006). Mail and phone interventions for weight loss in a managed-care setting: Weigh-to-be 2-year outcomes. *International Journal of Obesity*, 30, 1565-1573.
197. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. (2003). Standardized reporting of clinical practice guidelines; a proposal from the Conference on Guideline Standardization. *Annals of Internal Medicine*, 139, 493-498.
198. Southard BH, Southard DR, Nuckolls J. (2003). Clinical trial of an Internet-based case management system for secondary prevention of heart disease. *Journal of Cardiopulmonary Rehabilitation*, 23, 341-348.
199. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. (2000). Primary prevention of coronary heart disease in women through diet and lifestyle. *New England Journal of Medicine*, 343(1), 16-22.
200. Stasenko M, Cheng YW, McLean T, Jelin AC, Rand L, & Caughey AB. (2010). Postpartum follow-up for women with gestational diabetes mellitus. *American Journal of Perinatology*, 27(9), 737-742.
201. Stromberg A and Martensson J. (2003). Gender differences in patients with heart failure. *European Journal of Cardiovascular Nursing*, 2(1), 7-18.
202. Surgeon General's Call-to-Action 2007 Overweight and Obesity. What You Can Do: Being Physically Active Can Help You Attain or Maintain a Healthy Weight. Available at:
http://www.surgeongeneral.gov/topics/obesity/calltoaction/fact_whatcanyoudo.htm.
203. Toh SD, Hernández-Díaz S, Logan R, Rossouw JE, & Hernán MA. (2010). Coronary heart disease in postmenopausal recipients of estrogen plus progestin

- therapy: Does the increased risk ever disappear? A randomized trial. *Annals of Internal Medicine*, 152(4), 211-217.
204. Tong VT, Jones JR, Dietz PM, D'Angelo D, & Bombard JM (2009). Trends in smoking before, during, and after pregnancy - Pregnancy risk assessment monitoring system (PRAMS), United States, 31 sites, 2000-2005. *Morbidity and Mortality Weekly Report*, 58 (SS-4), 1-29.
 205. U.S. Department of Health and Human Services. (1999). Physical activity and health: a Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion.
 206. Vaccarino V et al. (1999). Sex-based differences in early mortality after myocardial infarction. National registry of myocardial infarction 2 participants. *New England Journal of Medicine*, 341(4), 217-225.
 207. Vasan RS, Sullivan LM, Wilson PWF, Sempos CT, Sundstrom J, Kannel WB, Levy D, D'Agostino RB. (2005). Relative importance of borderline and elevated levels of coronary heart disease risk factors. *Annals of Internal Medicine*, 142, 393-402.
 208. Wassertheil-Smoller S, et al. (2004). Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). *Archives of Internal Medicine*, 164, 289-98.
 209. Wheeler JR, Janz NK, Dodge JA. (2003). Can a disease self-management program reduce health care costs? The case of older women with heart disease. *Medical Care*, 41, 706-715.
 210. Whitlock EP, et al. (2003). The primary prevention of heart disease in women through health behavior change promotion in primary care. *Women's Health Issues*, 13, 122-141.
 211. Wild R, et al. (2010). Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome

- (AE-PCOS) Society. *Journal of Clinical Endocrinology & Metabolism*, 95(5), 2038-2049.
212. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. (2003). Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. *BMJ*, 326, 845-852.
213. Women's Health Initiative Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. *Journal of the American Medical Association*, 291, 1701-1712.
214. Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. *Journal of the American Medical Association*, 288, 321-333.
215. Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: Final data for 2007. National vital statistics reports; vol 58 no 19. Hyattsville, MD: National Center for Health Statistics. 2010.
216. Zethraeus N, Strom O, Borgstrom F, Kanis JA, Jonsson B. (2008). The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. *Osteoporosis International*, 19, 819-827.